Endonovo Therapeutics (OTCQB: ENDV) on Tuesday posted the company’s financial and operating results for the second quarter. The company reported revenues for the three months ended June 30, 2019 of $62,729, a sharp increase compared to $12,854 for the same period last year. Gross profits for the second quarter were $33,156, as compared to $12,304 … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Posts Q2 2019 Financial Results”
Endonovo Therapeutics (OTCQB: ENDV) is a developer of safe, wearable and non-invasive medical devices. The company’s SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. An article discussing the company reads, “SofPulse was recently rolled out in hospitals, nursing centers and wound care centers throughout the U.S. as an effective, postsurgical … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Positioning SofPulse as Natural Post-Surgical Alternative to Opioids”
Endonovo Therapeutics (OTCQB: ENDV) is a commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices that target patient pain and inflammation while supporting wound recovery. An article discussing the company reads, “Targeting inflammatory conditions in vital organs and peripheral tissues, Endonovo’s SofPulse(R) is clinically proven to significantly speed the recovery process and reduce the need for potentially … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc.’s (ENDV) SofPulse Safely Reduces Pain, Swelling”
Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and … Continue reading “NetworkNewsAudio – Endonovo Therapeutics Inc. (ENDV) Interview”
While the post-operative pain management market is anticipated to grow, the U.S. is looking for alternatives to traditional opioid administration Endonovo has alternative technologies that allow for effective pain and swelling management, bringing down the need for the administration of opioids Endonovo announced the rollout of its therapeutic device in hospitals and pain management centers … Continue reading “Endonovo Therapeutics Inc. (ENDV) Delivering Safe Patient Recovery Tech as Alternative to Traditional Opioid Pain Management Solutions”
Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(TM) therapeutic devices, this morning announced its appointment of Peter Novak, M.D., Ph.D., to its scientific advisory board. According to the update, Novak is a board-certified neurologist and autonomic specialist who serves as the director of the Autonomic Laboratory at the Department of Neurology, Brigham … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Appoints Dr. Peter Novak to Scientific Advisory Board”
Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, recently named Dr. Steven Levin, M.D., to its scientific advisory board. An article further discussing the appointment reads, “‘Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain-management field, as well as his strong research interest to improve clinical practice in pain management, will be … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Adds National Leader to Scientific Advisory Board”
Proprietary bioelectronic devices developed by Endonovo Therapeutics target patient pain and inflammation while aiding wound recovery SofPulse® safely decreases pain by reducing edema (swelling), which decreases the need for prescription pain medications Endonovo’s wearable device can be used to address an array of medical conditions and is FDA-cleared for treating post-operative pain and edema in … Continue reading “Endonovo Therapeutics Inc. (ENDV) Offers Non-Narcotic, Non-Invasive Power of SofPulse to Help Patients Recover More Quickly”
Appointment of Dr. Steven Levin of Johns Hopkins University to Endonovo’s scientific advisory board is expected to help facilitate the introduction of Endonovo’s non-invasive bio-electrical medical devices to hospitals and clinics The global wearable medical devices market is expected to grow to nearly $67 billion by 2026 at a CAGR of 26.1 percent Endonovo holds … Continue reading “Endonovo Therapeutics Inc. (ENDV) Appoints National Leader in Pain Management to Scientific Advisory Board”
As part of its goal to reduce post-operative drug dependence, innovative biotechnology company Endonovo Therapeutics (OTCQB: ENDV) recently revealed plans to get its flagship SofPulse Therapy Device into 600 hospitals within the next 18 months. An article further discussing the company reads, “On June 13, the company detailed its initial strategy for a national rollout … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Details National Rollout of Natural, Safe Alternative to Opioids”
